Aaron J Blashill1, Steven A Safren. 1. Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, The Fenway Institute, Boston, Massachusetts.
Abstract
OBJECTIVES: We compared the lifetime prevalence of anabolic-androgenic steroid (AAS) misuse among sexual minority versus heterosexual U.S. adolescent boys, and secondarily, sought to explore possible intermediate variables that may explain prevalence differences. METHODS: Participants were 17,250 adolescent boys taken from a pooled data set of the 14 jurisdictions from the 2005 and 2007 Youth Risk Behavior Surveys that assessed sexual orientation. Data were analyzed for overall prevalence of AAS misuse and possible intermediary risk factors. RESULTS: Sexual minority adolescent boys were at an increased odds of 5.8 (95% confidence interval 4.1-8.2) to report a lifetime prevalence of AAS (21% vs. 4%) compared with their heterosexual counterparts, P < .001. Exploratory analyses suggested that increased depressive symptoms/suicidality, victimization, and substance use contributed to this disparity. CONCLUSIONS: This is the first known study to test and find substantial health disparities in the prevalence of AAS misuse as a function of sexual orientation. Prevention and intervention efforts are needed for sexual minority adolescent boys.
OBJECTIVES: We compared the lifetime prevalence of anabolic-androgenic steroid (AAS) misuse among sexual minority versus heterosexual U.S. adolescent boys, and secondarily, sought to explore possible intermediate variables that may explain prevalence differences. METHODS:Participants were 17,250 adolescent boys taken from a pooled data set of the 14 jurisdictions from the 2005 and 2007 Youth Risk Behavior Surveys that assessed sexual orientation. Data were analyzed for overall prevalence of AAS misuse and possible intermediary risk factors. RESULTS: Sexual minority adolescent boys were at an increased odds of 5.8 (95% confidence interval 4.1-8.2) to report a lifetime prevalence of AAS (21% vs. 4%) compared with their heterosexual counterparts, P < .001. Exploratory analyses suggested that increased depressive symptoms/suicidality, victimization, and substance use contributed to this disparity. CONCLUSIONS: This is the first known study to test and find substantial health disparities in the prevalence of AAS misuse as a function of sexual orientation. Prevention and intervention efforts are needed for sexual minority adolescent boys.
Entities:
Keywords:
adolescents; anabolic-androgenic steroids; boys; sexual orientation
Authors: Michael P Marshal; Mark S Friedman; Ron Stall; Kevin M King; Jonathan Miles; Melanie A Gold; Oscar G Bukstein; Jennifer Q Morse Journal: Addiction Date: 2008-04 Impact factor: 6.526
Authors: L Goldberg; D Elliot; G N Clarke; D P MacKinnon; E Moe; L Zoref; C Green; S L Wolf; E Greffrath; D J Miller; A Lapin Journal: JAMA Date: 1996-11-20 Impact factor: 56.272
Authors: Gen Kanayama; Matthew Boynes; James I Hudson; Alison E Field; Harrison G Pope Journal: Drug Alcohol Depend Date: 2006-11-28 Impact factor: 4.492
Authors: Elizabeth W Diemer; Julia D Grant; Melissa A Munn-Chernoff; David A Patterson; Alexis E Duncan Journal: J Adolesc Health Date: 2015-04-28 Impact factor: 5.012
Authors: Jason M Nagata; Stuart B Murray; Kirsten Bibbins-Domingo; Andrea K Garber; Deborah Mitchison; Scott Griffiths Journal: Int J Eat Disord Date: 2019-06-20 Impact factor: 4.861
Authors: Gregory Phillips; Blair Turner; Paul Salamanca; Michelle Birkett; Mark L Hatzenbuehler; Michael E Newcomb; Rachel Marro; Brian Mustanski Journal: Drug Alcohol Depend Date: 2017-06-29 Impact factor: 4.492